ArticleCancers2020

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies.

Christie P M Verkleij et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.